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Introduction 
Argininosuccinic aciduria (ASA; OMIM 207900) is an autosomal recessive metabolic disorder caused by argininosuccinate lyase (ASL; MIM 608310) deficiency, 
and it is the second most frequent urea cycle disorder (UCD), with an estimated frequency of 1:70 000. 
The human ASL gene (MIM 608310) is located on chromosome 7q11.21 and comprises 16 exons encoding a 464 amino acids long monomer. The enzyme is 
functional in a homotetrameric structure and is mainly expressed in the liver, although it can be found in several other tissues (Hu et al. 2013). 
The clinical presentation of ASA is very heterogeneous, ranging from asymptomatic to severe hyperammonemic neonatal-onset cases. Complex clinical 
phenotypes, with neurological deficits and hepatic complications adding to hyperammonemic episodes, are often observed (Nagamani et al. 2012). 
Biochemically, ASA is usually characterized by elevation of both citrulline and argininosuccinic acid in plasma and urine, but also at this level heterogeneity is 
observed, adding to a poor correlation found between residual enzymatic activity and the severity of the clinical phenotype. 
ASA newborn screening (NBS) is done in Portugal since 2004, and two cases of late-onset ASA were missed due to normal citrulline and argininosuccinic acid 
levels at sampling time. 
Material and Methods 
The Portuguese NBS Program started to include tandem mass spectrometry (ms/ms) analysis for inborn errors of metabolism screening in 2004. Amino acids 
and acylcarnitines are analyzed as butyl esters (Rashed et al. 1995), using two API 2000 triple quadrupole tandem mass spectrometers (Applied Biosystems, 
Sciex), and quantified using internal standards from Cambridge Isotope Laboratories, Inc.. 
ASA is screened according to Table 1. Argininosuccinic acid, citrulline and arginine quantification are performed by multiple reaction monitoring (MRM) 
experiments as indicated in Table 2. 
Approximately nine hundred thousand newborns were already screened by ms/ms, through the analysis of blood samples collected between the 3rd and the 
6th days of life on Whatman 903 filter paper. 
Positive cases were confirmed by amino acids analysis in urine and molecular analysis, according to standard protocols. 
Table 1 – Positive screening criteria for Argininosuccinic aciduria 
Table 2 – ms/ms detection of argininosuccinic acid, citrulline and arginine 
Primary marker Secondary markers 
Argininosuccinic acid >1.1 µM 
Citrulline >50 µM 
Citrulline/ Arginine > 10 
Compound Internal standard 
MRM transition 
(m/z) 
Arginine 2H4; 5-
13C-Arginine 231→70 
Citrulline 2H2-Citrulline 232→113 
Argininosuccinic acid 2H2-Citrulline 459→70 
Results 
Four ASA patients were screened (Table 3): two cases were identified by 
NBS (patients 1 and 3) and two brothers presented normal results at NBS 
sampling time (patients 2 and 4).  
These brothers presented a late-onset form of ASA and the study of ASL 
gene revealed homozigosity for R12Q mutation. 
Table 3 – Patients characterization and NBS results 
Patients 2 and 4 are brother and sister. 
M–male; F-female; y-years; m-months; d-days; w-weeks; a Linnebank et al. 2002; b Walker et al. 1990; 
cSampaleanu et al. 2001; d Kleijer et al. 2002 
Conclusions 
ASA NBS utility is firmly established due to the benefits that early 
therapy can bring to the patients. Nevertheless, care must be taken 
due to the possibility of missing late-onset cases.  
Discussion 
Patient 2, which is the oldest brother of patient 4, started to be 
investigated in the first months of age due to developmental delay. 
Plasmatic amino acids quantification was performed during his first 
year of live, with a consistent slight increase in citrulline, but only at 
16 months the detection of a small amount of argininosuccinic acid in 
plasma raised the suspicious of a late-onset form of ASA. 
This diagnosis was confirmed by identification of R12Q mutation, in 
homozygosity, in ASL gene. This mutation was reported to be 
associated with a mild clinical form of the disease and frequently 
found in late-onset ASA cases (Balmer et al. 2013).  
Last June a sister of this patient was born. In spite of the normal NBS 
biochemical result (Table 3), and due to her brother’s history, we 
recommended the molecular study, which also revealed homozygosity 
for R12Q mutation. This girl immediately started treatment and to 
date is clinically well, without any ASA symptoms, and thus reinforcing 
the importance of early treatment for this disease. 
Newborn screening for ASA is widely established although some 
paradoxal results can be obtained due to the clinical and biochemical 
ASA heterogeneity: asymptomatic cases can be detected and, on the 
contrary, late-onset forms with important clinical manifestations 
observed since the first months of live can be missed due to normal 
biochemical results. 
Patient Sex 
Actual 
age 
Age at 
NBS 
Age at 
diagnosis 
NBS result Molecular study 
1 F 8y 4d 6d 
Cit=186µM (N<50µM) 
c.446+1G>Aa / 
p.Q286Rb 
ASA=134,0µM (N<1,1µM) 
Cit/Arg= 39,0 (N<10) 
2 M 5y 4d 16m 
Cit=23µM (N<50µM) 
p.R12Qc / R12Q ASA=0,90µM (N<1,1µM) 
Cit/Arg= 1,5 (N<10) 
3 F 4y 11d 1m 
Cit=34µM (N<50µM) 
p.R379Cd / 
p.R379C 
ASA=5,4µM (N<1,1µM) 
Cit/Arg= 3,7 (N<10) 
4 F 8m 3d 3w 
Cit= 24µM (N<50) 
p.R12Q / R12Q ASA= 0.26µM (N<1.1) 
Cit/Arg= 2.1 (N<10)  
